RT Conference Proceedings
T1 Pattern of CNS relapse in acute lymphoblastic leukemia BCR-ABL positive, the importance of characterization of ABL1 mutations in cerebrospinal fluid.
A1 Sanchez, R
A1 Ayala, R
A1 Alonso, RA
A1 Ribera, J
A1 García, O
A1 Mercadal, S
A1 Montesinos, P
A1 Martino, R
A1 Barba, P
A1 González-Campos, J
A1 Barrios, M
A1 Lavilla, E
A1 Gil, C
A1 Bernal, T
A1 Escoda, L
A1 Abella, E
A1 Amigo, ML
A1 Moreno, MJ
A1 Bravo, P
A1 Guàrdia, R
A1 Hernández-Rivas, JM
A1 García-Guiñón, A
A1 Piernas, S
A1 Ribera, JM
A1 Martínez-López, J
K1 Médula ósea
K1 Evolución clonal
K1 ADN complementario
K1 Proteínas de fusión bcr-abl
K1 Humanos
K1 Mesilato de imatinib
K1 Incidencia
K1 Masculino
K1 Sistema nervioso
K1 Leucemia-linfoma linfoblástico de células precursoras
K1 Recurrencia
K1 Tirosina
AB He incidence of central nervous system (CNS) relapse among; patients with BCR/ABL-positive acute lymphoblastic leukemia (ALL) is 8-17%. Although tyrosine-kinase inhibitors (TKI), especially imatinib, are included in; the first-line treatment in these patients, their concentration in CNS is too low; to effectively prevent CNS relapse, making CNS prophylaxis mandatory. Aims: To study the frequency, predictors and evolution of BCR-ABL positive; ALL patients with CNS relapse in two consecutive clinical trials of the PETHEMA; group using imatinib and chemotherapy. As secondary objective we proposed; the introduction of a new method for the study of variants of uncertain; significance (VUS) in kinase domain of the BCR-ABL from cDNA of cerebrospinal; fluid (CSF) blasts, in order to adapt the TKI used in relapse according; to the clonal evolution from bone marrow (BM) to CSF cells.
PB Ferrata Storti Foundation
SN 0390-6078
YR 2016
FD 2016-06
LK http://hdl.handle.net/10668/2444
UL http://hdl.handle.net/10668/2444
LA en
NO Sanchez R, Ayala R, Alonso RA, Ribera J, García O, Mercadal S, et al. Pattern of CNS relapse in acute lymphoblastic leukemia BCR-ABL positive, the importance of characterization of ABL1 mutations in cerebrospinal fluid. Haematologica. 2016. 101 (s1) E865
DS RISalud
RD Apr 18, 2025